Foghorn Therapeutics Inc

Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company that discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within this system. It is developing therapies for mutant non-small cell lung, endometrial, cervical, ovarian, and bladder cancers, as well as diffuse large B-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome. The company has a collaboration agreement with Eli Lilly and Company to develop FHD-909, a selective ATPase inhibitor of BRM. Incorporated in 2015, it is headquartered in Watertown, Massachusetts.